gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Vascular Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beranek, J; Binkert, CA; Eckhardt, B; Froehlich, JM; Gutzeit, A; Jenelten, R; Wentz, KU; Willemse, E | 1 |
Bautz, W; Dobritz, M; Fellner, C; Fellner, F; Janka, R; Lang, W; Lenz, M | 1 |
2 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Vascular Diseases
Article | Year |
---|---|
Clinical experience in timed arterial compression contrast-enhanced magnetic resonance angiography of the hand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Female; Hand; Heterocyclic Compounds; Humans; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Male; Middle Aged; Organometallic Compounds; Radial Artery; Reproducibility of Results; Retrospective Studies; Ulnar Artery; Vascular Diseases; Young Adult | 2010 |
Gd-BOPTA: "the MRA contrast agent of choice"?
Topics: Aortic Valve Stenosis; Chelating Agents; Contrast Media; Gadolinium; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Meglumine; Organometallic Compounds; Subclavian Artery; Vascular Diseases | 1999 |